ADCT

ADC Therapeutics (ADCT)

About ADC Therapeutics (ADCT)

ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.

Details

Daily high

$4.26

Daily low

$4.06

Price at open

$4.23

52 Week High

$4.80

52 Week Low

$1.05

Market cap

524.0M

Dividend yield

0.00%

Volume

2.5M

Avg. volume

1.7M

P/E ratio

-2.92

ADC Therapeutics News